PMN

ProMIS Neurosciences Presentation: ProMIS Neurosciences Inc. will deliver virtual presentations at the 2025 Alzheimer's and Parkinson's Disease International Conference, showcasing their innovative approaches to developing antibody therapeutics and vaccines targeting toxic misfolded proteins linked to neurodegenerative diseases like Alzheimer's, ALS, and MSA.

Research Findings: The company’s preclinical studies indicate promising results for their vaccine candidates, including PMN310, which selectively targets toxic amyloid-beta oligomers and aims to provide effective treatment options while preserving normal protein functions in the brain.

Company Announcement: ProMIS Neurosciences, Inc. will have its CEO Neil Warma participate in a fireside chat at the 37th Annual Roth Conference on March 18, 2025, focusing on their development of antibody therapeutics for neurodegenerative diseases.

Product Development: The company is advancing its lead product candidate, PMN310, a monoclonal antibody targeting toxic Aβ oligomers associated with Alzheimer's disease, which has completed Phase 1a trials and is currently in Phase 1b trials.

Progress in Alzheimer's Treatment: ProMIS Neurosciences has initiated dosing of multiple patients in its Phase 1b clinical trial for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers, aiming to address the urgent need for effective Alzheimer's treatments.

Future Expectations: Interim results from the PRECISE-AD trial are expected in the first half of 2026, with topline results anticipated in the second half of 2026, as the study seeks to evaluate safety, tolerability, and potential efficacy of PMN310 in Alzheimer's patients.

Company Announcement: ProMIS Neurosciences, Inc. will have its CEO Neil Warma participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, focusing on their antibody therapeutics for neurodegenerative diseases.

Product Development: The company is advancing its lead product candidate, PMN310, a monoclonal antibody designed to target toxic Aβ oligomers in Alzheimer's disease, having completed a Phase 1a clinical study and initiated a Phase 1b trial.

Company Progress: ProMIS Neurosciences has transitioned to a clinical-stage biotechnology company, successfully completing its Phase 1a trial for PMN310, a potential treatment for Alzheimer's disease, and initiating a Phase 1b trial with positive preliminary results.

Future Aspirations: The company is focused on developing targeted therapies for neurodegenerative diseases, with plans to advance additional candidates in their pipeline while enhancing their intellectual property portfolio.

Initiation of Clinical Trial: ProMIS Neurosciences has launched a Phase 1b clinical trial (PRECISE-AD) for its Alzheimer's disease treatment candidate, PMN310, which targets toxic amyloid-beta oligomers while minimizing side effects associated with existing therapies.

Potential Impact and Future Plans: The trial aims to evaluate the safety and efficacy of PMN310 in patients with mild cognitive impairment or early Alzheimer's, with results expected to inform further development and potential therapeutic options for the disease.

Clinical Trial Progress: ProMIS Neurosciences reported positive results from its Phase 1a clinical trial of PMN310, an antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease, indicating it was well-tolerated and showed potential for target engagement. The company plans to initiate a Phase 1b trial by the end of 2024.

Financial Update: The company completed a PIPE financing that could yield up to $122.7 million, significantly increasing its cash reserves to $21.5 million as of September 30, 2024, while reporting a net income of $9.3 million for the quarter, primarily due to gains on warrant liabilities.

ProMIS Neurosciences Insider Buying: Director Madge K. Shafmaster purchased 200,000 shares of PMN at $1.28 each, totaling $255,750, and saw a 13.4% gain during trading as PMN reached $1.45.

Biohaven Insider Activity: Director Gregory Bailey bought 5,000 shares of BHVN for $44.19 each, totaling $220,966, and has previously invested $3.91M in the company over the past year, currently up 11.4% based on today's high of $49.24.

Market Overview: The Dow Jones index fell by over 100 points, highlighting investor sentiment influenced by insider trading activities in penny stocks, which can indicate confidence or concern regarding company prospects.

Recent Insider Transactions: Notable insider purchases include WidePoint's CEO buying shares at $3.50 each, ProMIS Neurosciences' owner acquiring shares at $1.25, and Emmaus Life Sciences' director purchasing shares for $0.04, reflecting varying company performances and market strategies.

Exicure's Stock Surge: Exicure, Inc. shares rose 179.9% in pre-market trading after receiving an extension from the Nasdaq Hearings Panel to maintain its listing, with a compliance deadline set for November 14.

Market Movements: Other notable pre-market stock movements included Zeo Energy Corp. gaining 288.9%, while Progyny, Inc. saw a decline of 23.2%.

ProMIS Neurosciences' Presentation: ProMIS Neurosciences Inc. announced that preclinical data for its lead product candidate, PMN310, targeting toxic amyloid-beta oligomers in Alzheimer's disease will be presented at the 4th International Conference on Cognitive & Behavioral Neurosciences in Lisbon, Portugal.

PMN310's Selectivity and Efficacy: The therapeutic antibody PMN310 is designed to selectively target toxic oligomers without binding to non-toxic species, potentially improving efficacy and reducing risks associated with amyloid-related imaging abnormalities compared to other antibodies.

Prospectus Filing: ProMIS Neurosciences filed a prospectus for the resale of up to 56,514,784 common shares by selling securityholders.

Clarification: The prospectus is not an offer to sell the shares.

Insider Transactions: Recent notable insider transactions in penny stocks include Pineapple Financial's CEO buying 2,000 shares at $1.08, ProMIS Neurosciences' director acquiring 10,000 shares at $1.25, and Standard BioTools' director purchasing 1.2 million shares at $1.59, reflecting varying levels of confidence amid financial challenges.

Company Overviews: Pineapple Financial is a mortgage technology company, ProMIS Neurosciences focuses on antibody therapeutics for neurodegenerative diseases, and Standard BioTools develops technologies for biomedical research, all facing recent financial setbacks.

Ainos, Inc. Stock Surge: Ainos, Inc. shares rose 37.7% in pre-market trading after the company secured exclusive licenses for 10 invention patents from Taiwan Carbon Nano Technology.

Market Movements: Several stocks experienced significant changes, with LogicMark, Inc. gaining 49%, while Meta Materials Inc. saw a decline of 27.7% following its bankruptcy announcement.

Top Gainers: Notable pre-market stock movers include PS International Group (up 81%), Ainos (up 47% due to new patent licenses), and LogicMark (up 38% ahead of a shareholder meeting), among others showing significant increases.

Top Losers: Major declines were seen in iLearningEngines (down 27% after a public offering), Meta Materials (down 17% following bankruptcy filing), and Sonoma Pharmaceuticals (down 15% after missing earnings estimates).

Earnings Report: ProMIS Neurosciences reported a second-quarter 2024 earnings per share of -13 cents, surpassing the analyst estimate of -14 cents, but did not generate any revenue for the quarter.

Automated Coverage: InvestorPlace Earnings utilizes TradeSmith data to automate the reporting of quarterly earnings, providing quick insights on key financial metrics without human intervention.

Company Announcement: ProMIS Neurosciences Inc. will have its interim CEO Neil Warma and Chief Medical Officer Larry Altstiel participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024.

Company Focus: ProMIS Neurosciences is a biotechnology firm dedicated to developing therapeutics targeting toxic misfolded proteins associated with neurodegenerative diseases like Alzheimer's, ALS, and MSA using their proprietary discovery platform.

Preclinical Data on Alzheimer's Vaccine: ProMIS Neurosciences presented promising preclinical data at the 2024 Alzheimer's Association International Conference, showing strong antibody responses and no pro-inflammatory T cell responses against toxic amyloid-beta oligomers (AβO), supporting their novel approach to an Alzheimer's vaccine.

Potential for Preventative Treatment: The findings suggest that the PMN310 antibody and AβO vaccine candidates could potentially be used as a preventative measure for at-risk individuals or therapeutically to inhibit the progression of Alzheimer's disease in diagnosed patients.

Saia, Inc Financial Results: Saia, Inc. shares dropped 18.6% after reporting second-quarter earnings of $3.83 per share, missing the analyst estimate of $4.00, and sales of $823.24 million, below the expected $826.55 million.

Stock Movements: Several stocks saw significant gains, including BurgerFi International (+117.4%) and Coursera (+46.2%), while others like NovaBay Pharmaceuticals (-59.6%) and DexCom (-40.7%) experienced sharp declines following disappointing financial results.

Clinical Trial Results: ProMIS Neurosciences announced positive results from the Phase 1a clinical trial of its antibody PMN310, showing a favorable safety profile and dose-dependent engagement in cerebrospinal fluid, indicating potential effectiveness for Alzheimer's disease treatment.

Future Developments: The company plans to advance PMN310 into a Phase 1b trial in Alzheimer's patients later in 2024, building on the encouraging data that suggests PMN310 could selectively target toxic amyloid-beta oligomers associated with Alzheimer's pathology.